SCHEMBL8109949

SCHEMBL8109949

CC(=O)CCC(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.50
EPHX2 P34913 5/20 0.44
TBXA2R P21731 1/20 0.44
CYP19A1 P11511 2/20 0.42
SLC6A3 Q01959 2/20 0.42
FAAH O00519 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
MTOR P42345 1/20 0.42
RAB9A P51151 1/20 0.42
CACNA1F O60840 1/20 0.42
HTR1A P08908 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
DRD4 P21917 1/20 0.42
DRD5 P21918 1/20 0.42
HRH2 P25021 1/20 0.42
ADRA1D P25100 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67228 0.84 CACNA1B (0.53) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
SCHEMBL8141135 0.83 HTT (0.42) TSHRHPGDLMNA
SCHEMBL11543107 0.82 MTNR1A (0.58) EPHX2HTR2AHRH1
SCHEMBL13130720 0.81 CACNA1B (0.48) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
SCHEMBL2862307 0.81 CACNA1B (0.54) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
SCHEMBL9538154 0.81 CACNA1B (0.50) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
SCHEMBL10439829 0.80 HPGD (0.54) CACNA1BCYP3A4CYP2D6TSHRCACNA1C
SCHEMBL7323763 0.79 CACNA1B (0.49) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
Hydrochloric Acid SCHEMBL7389220 0.79 CACNA1B (0.55) CACNA1BEPHX2TBXA2RCYP19A1SLC6A3
SCHEMBL12587804 0.78 AOC3 (0.46) TBXA2RCYP2D6RAB9AHTR7GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563732-B2 Oxyimino compounds and the use thereof SHIONOGI & CO., LTD. (JP) 2013-10-22 US disclosed
US-20100240703-A1 OXYIMINO COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2010-09-23 US disclosed
WO-2008150470-A1 OXYIMINO COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-12-11 WO disclosed
US-5137896-A Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent JANSSEN PHARMACEUTICA N.V. (BE) 1992-08-11 US disclosed
US-5057525-A Stimulators of gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1991-10-15 US disclosed
US-4962115-A Stimulate motility of gastrointestinal system JANSSEN PHARMACEUTICA N.V. (BE) 1990-10-09 US disclosed
EP-0076530-B1 NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-11 EP disclosed
EP-0076530-A2 Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1983-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240703-A1 OXYIMINO COMPOUNDS AND THE USE THEREOF CACNA1A, CACNA1S, OPRM1 CACNA1B 8/4885EPHX2 653/4885TBXA2R 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.